Here you can learn more about isotopic metallome, find our overviews, white papers, patents, and third party research in support of our scientific stance, and many more...
Here you can learn more about isotopic metallome, find our overviews, white papers, patents, and third party research in support of our scientific stance, and many more...
64Zn Aspartate Enhances Apoptosis in MB16 Cancer While Sparing Normal Cells
This white paper presents an evaluation of 64Zn-Asp cytotoxicity against MB16 and A-549 cells in vitro, assesses the 64Zn-Asp cancer-specific effects, and contemplates a hypothesis for 64Zn-Asp mechanism of action acting as isotope-selective PARP1 inhibitor.
In Vitro Anticancer Activity of Light Stable Zinc Isotope (64Zn) Compounds
This publication presents evaluation of cytotoxic activity of our first therapeutic drug candidate based of light zinc isotope 64Zn enriched to >99% against MB16 melanoma and L1210 leukemia cells malignant cells.
First-in-Human Study of KLS-1 (64Zn L-Aspartate)
This publication presents our small, non-registrational, first-in-human "learning" study of our KLS-1 drug candidate (64Zn enriched to >99%) in patients with oncological and neurodegenerative diseases. The purpose of this study was to establish initial dose of KLS1 for treatment of patients with various pathologies prior to conducting full-scale registrational Phase 1 clinical trial.
Anti-inflammatory Effects of 64Zn-Asp Accompanied by Cognitive Improvements in AD
This publication discusses our study for KLS-1 administration in rats with Aβ1-40-induced Alzheimer's disease (AD.) The article outlines our perspective on targeting systemic and neuroinflammation in AD and presents findings from our preclinical investigation in this area. The purpose of this study was to assess the effect of intravenous administration of novel investigational drug substance, 64Zn aspartate (KLS-1), on local and systemic inflammation and on cognitive parameters in rats with Aβ1-40-induced AD.
Therapeutic Potential of Isotopically Modified 64Zn Aspartate for Obesity Management
This publication outlines our perspective on targeting obesity with the first-in-class, first-in-humans isotope selective modulator, KLS-1, and presents findings from our preclinical investigation in this indication. The purpose of this study was to assess the effect of 64Zn aspartate (KLS-1) on body mass, appetite, oxidative stress, and histopathological changes in pancreas and liver in Diet-Induced Obesity rodent model. The results show that KLS-1 slows down the development of obesity by 56% while improving the liver and pancreas functions.
Treatment With Isotopically Modified 64Zinc-Asp Alleviates Neuroinflammation and Motor Dysfunction in PD
This white paper outlines our perspective on targeting systemic inflammation in Parkinson's disease (PD) and presents our preclinical findings. The purpose of this study was to assess the effect of intravenous administration of novel investigational drug substance, 64Zn aspartate (KLS-1), on local and systemic inflammation and on cognitive parameters in rats with LPS-induced PD.
Zinc Dysregulation in Cancers and Its Potential As A Therapeutic Target
This review briefly summarizes the current understanding of zinc dyshomeostasis in cancer, and discusses the potential roles of zinc or zinc transporters in cancer therapy. The review is focused on isotopically natural zinc and does not discuss any possible isotope effects.
Investigations of Zinc Isotope Fractionation in Breast Cancer Tissue Using In-Vitro Cell Culture Uptake-Efflux Experiments
This review reports isotopic data for Zn uptake-efflux experiments using a human breast cancer cell line. MDA-MB-231 cell line was used as a model for triple receptor negative breast cancer. Zn isotopic composition in clinical samples of breast cancer tissue are analyzed relative to healthy tissue.
Zinc isotope ratios of bones and teeth - Results from a modern food web
This review reports the measurements of the ratio of stable isotopes of zinc (δ66Zn) in bioapatite (bone and dental enamel) of animals and demonstrates that δ66Zn values in both bone and enamel allow a clear distinction between carnivores and herbivores.
The beneficial effect of zinc on low-dose chemotherapeutic sensitivity involves wtp53 activation in cancer cells
This review addresses that zinc supplementation might have a beneficial antitumor effect in wild-type p53-carrying cells in combination with other drugs, and that mutant p53 proteins undergo protein misfolding that can be counteracted by zinc.
Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets
This review consolidates the knowledge on the critical functions of cellular zinc signaling and underscores potential molecular pathways linking zinc metabolism to disease progression, with a special focus on cancer. The review also compiles a summary of clinical trials involving zinc ions.
Inflammatory Hallmarks in 6-OHDA- and LPS-induced Parkinson's Disease in Rats
Inflammatory Hallmarks in 6-OHDA- and LPS-induced Parkinson's Disease in Rats
This publication presents a comparison of activation patterns of microglia/macrophage population and systemic inflammation indices in rats with 6-Hydroxydopamine (6-OHDA)- and Lipopolysaccharide (LPS)-induced animal models of Parkinson's Disease. This is essential for maximizing the translation of their potential to the clinic, as well as for developing putative anti-inflammatory neuroprotective agents.
Systemic Inflammation in Aβ1-40-induced Alzheimer’s Disease Model: New Translational Opportunities
Systemic Inflammation in Aβ1-40-induced Alzheimer’s Disease Model: New Translational Opportunities
Neuroinflammation is associated with the impairment of blood–brain barrier and leakage of inflammatory mediators into the periphery with developing systemic inflammatory responses. Systemic inflammation is considered one of the therapeutic targets for AD treatment that necessitates in-depth study of this phenomenon in appropriate non-transgenic animal models. This publication discusses inflammation as one of the therapeutic targets for treatment of Alzheimer's disease (AD.)
Alternative Cancer Treatments & The New Biology of Water.
A very interesting opinion from Dr. Thomas Cowan.